Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02626000 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02626000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
April 6, 2016
Completion date
August 28, 2020
Enrollment
36 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma of the head and neck